We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Immunoassay Developed for Legionnaires' Disease

By LabMedica International staff writers
Posted on 29 Sep 2011
Separate measurement of antibodies to Legionella pneumophila serogroups as single antigens can facilitate an early diagnosis of Legionnaires' disease.

An enzyme-linked immunosorbent assay (ELISA) was developed and evaluated to determine whether separate measurement of immunoglobulin (Ig) M and G antibodies to L. More...
pneumophila serogroups 1, 3 and 6 as single antigens can assist in the diagnosis.

Scientists at the Statens Serum Institut (Copenhagen, Denmark) compared the ELISA with an in-house indirect Legionella immunofluorescence antibody test (IFAT) measuring Total Ig. A total of 193 sera from 128 patients with confirmed L. pneumophila infections were used to assess the sensitivity of the developed ELISA. The sensitivity was assessed in different time-periods after onset of symptoms. L. pneumoniae infection was confirmed by one or more of the following methods: culture by standard method, Legionella urinary antigen EIA (Biotest AG, Dreieich, Germany), and an in-house polymerase chain reaction (PCR) method.

It was found that the sensitivity of the ELISA increased during the first month of infection, IgM being the most sensitive; ranging from 13% in the first week after onset of symptoms, 45% in the second week to 84% in the third week; in the fourth week and beyond, a drop to 67% was discerned. The IFAT detecting L. pneumophila subgroups 1–6 had a sensitivity of 11%, 27%, 80%, and 59%, respectively, during these time-periods. The test with the lowest sensitivity during these time-periods was the IgG ELISA (0%, 21%, 36%, and 52%) respectively, but by combining the IgG results with the IgM results, the overall sensitivity of the assay was improved (13%, 48%, 88%, and 70%), respectively.

The in-house methods IgM ELISA and IFAT both had a low false positive rate: 7% and 4% among 75 samples. In contrast, the IgG ELISA had a false positive rate of 14%, which was high compared to the other tests. The sera which were positive for Helicobacter pylori, Salmonella typhimurium/enteritidis, and Mycoplasma pneumoniae showed the highest rate of false positive in the IgG subgroup1 ELISA. The sera, which caused the false positive results in the IFAT and IgM ELISA were the sera with antibodies to Proteus species and S. typhimurium/enteritidis.

The study confirmed that detection of IgG and IgM antibodies by ELISA is an important diagnostic tool especially during the initial phase of the disease, when supported by other tests like the urinary antigen test, PCR, or culture of the organism. The authors concluded that specific antibodies against L. pneumophila subgroups 1, 3, and 6 can be detected in patients early in the course of infection. Furthermore, positive IgM level can be used as a good indicator of an ongoing or recent Legionella infection. The study was published in September 2011, in the Journal of Microbiological Methods.

Related Links:
Statens Serum Institut
Biotest AG



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.